Have Acurx Pharmaceuticals insiders bought shares recently?

No open-market purchase by an insider of Acurx Pharmaceuticals was filed in the last 90 days. The latest on record was on Jan 8, 2025.

How often do Acurx Pharmaceuticals insiders buy and sell shares?

Since 2021, Acurx Pharmaceuticals insiders reported 13 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2025.

Who is selling Acurx Pharmaceuticals stock?

No open-market sale by an insider of Acurx Pharmaceuticals (ACXP) was filed with the SEC in the last 90 days.

Do members of Congress trade ACXP?

No trade in Acurx Pharmaceuticals (ACXP) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Acurx Pharmaceuticals (ACXP) insider trading

Q: When does Acurx Pharmaceuticals report its next results?

Acurx Pharmaceuticals's next results are expected on Mar 10, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at ACXP buy and sell in the last 90 days?Which members of Congress and which funds traded ACXP recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

ACXP price and disclosed activity

−79.7% (−$3.78) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

No disclosed open-market insider trades, politician trades or fund 13F changes in this period.

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Insider open-market trades, filed in the last 90 daysNoneNo open-market trades reportedInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, last 12 monthsNoneNo followed fund reported a changeFund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in Staten Island, Ny.

Last 12 months

−79.8%

S&P 500 +12.3% over the same dates

Market value

$5.06M

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 98K shares sold short (1.9% of shares outstanding), +7.5% vs the previous count, 1.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

On the public record for Acurx Pharmaceuticals over the 12 months to Nov 14, 2026: 1 clinical trial.

Latest results: quarter ending Jun 30, 2026

Revenue

—

Free cash flow, last 12 months

—

Cash from operations minus capital spending

Net debt

—

Debt —, cash $10.7M, at Jun 30, 2026

Net income, last 12 months

−$7.51M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of May 13, 2025.

Insider buying and selling since 2021

Insiders of Acurx Pharmaceuticals reported 13 open-market purchases and 0 sales since 2021; purchases in 3 different years, most recently 2025.

Year	Bought	Sold
2025	$170K6×6 trades	—
2022	$225K3×3 trades	—
2021	$150K4×4 trades	—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

When insiders usually buy

Last results

May 13, 2025

More than 30 days ago

Next results, expected

Mar 10, 2027

after the market closes; the date can move until the company confirms it

Purchases after results

50%

6 of 12 insider purchases since 2021 came within 30 days after a results announcement

From Acurx Pharmaceuticals's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Acurx Pharmaceuticals's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.

Late-stage clinical trials

0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in clostridium difficile infection recurrence. The ones with the nearest registered primary completion date still ahead:

Sep 2027ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionPhase 2RecruitingClostridium Difficile Infection Recurrence

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

Latest

See everything

Insider buying

David P LuciPresident and CEO

Filed 2y ago

Bought

~$50K49K sh @ $1.02

Traded Jan 6, 2025 · filed 2 days later

The CEO of Acurx Pharmaceuticals paid $50K out of pocket for Acurx Pharmaceuticals shares. 5 other people at Acurx Pharmaceuticals bought some too, in the same month.

Want the short version?

Acurx Pharmaceuticals

How this filing works

Insiders who traded Acurx Pharmaceuticals

Other Pharmaceutical Preparations companies

Questions about Acurx Pharmaceuticals insider trading

ACXP price and disclosed activity

Latest results: quarter ending Jun 30, 2026

Insider buying and selling since 2021

When insiders usually buy

Late-stage clinical trials

Latest

~$50K49K sh @ $1.02

~$25K25K sh @ $1.02

~$25K25K sh @ $1.02

~$10K9,852 sh @ $1.02

~$10K9,852 sh @ $1.02

Late-stage clinical trials

Insider buying and selling since 2021

When insiders usually buy